|
業務類別
|
Biotechnology |
|
業務概覽
|
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab. |
| 公司地址
| 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850 |
| 電話號碼
| +1 240 745-6330 |
| 傳真號碼
| -- |
| 公司網頁
| http://www.novabridge.com |
| 員工數量
| 32 |
| Mr. Kyler Lei |
Chief Financial Officer |
-- |
31/10/2025 |
| Dr. Phillip Dennis, M.D.,PhD |
Chief Medical Officer |
-- |
31/10/2025 |
| Dr. Xi-Yong Fu |
Chief Executive Officer and Director |
-- |
31/10/2025 |
| Dr. Sean Cao |
Chief Business Development Officer and Director |
-- |
31/10/2025 |
| Dr. Claire Xu |
Senior Vice President, Clinical Development |
-- |
31/10/2025 |
|
|
| Mr. Wei Fu |
Executive Chairman of the Board |
31/10/2025 |
| Dr. Xi-Yong Fu |
Chief Executive Officer and Director |
31/10/2025 |
| Dr. Sean Cao |
Chief Business Development Officer and Director |
31/10/2025 |
| Dr. Robert Lenz, M.D. |
Independent Director |
31/10/2025 |
| Mr. Chia-hung Conor Yang |
Independent Director |
31/10/2025 |
| Ms. Xin Liu |
Independent Director |
31/10/2025 |
| Mr. Ian Ying Woo |
Director |
31/10/2025 |
| Mr. Chun Kwok Alan Au |
Independent Director |
31/10/2025 |
|
|
|
|
